# Domain Therapeutics

Source: https://onco.cc/companies/domain-therapeutics/  
OnCo record `domain-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Domain Therapeutics develops medicines aimed at a family of cell-surface receptors called GPCRs to help the immune system fight cancer. Its lead antibody removes the immune cells that shield tumours from attack.

## Summary

Domain Therapeutics SA, with communications datelined Strasbourg, France, Montreal, Canada and Boston, United States, describes itself as a clinical-stage company with over two decades of work on G protein-coupled receptors (GPCRs), focused on immuno-oncology and inflammation. Its anti-CCR8 monoclonal antibody DT-7012 is designed to deplete regulatory T cells inside tumours; the DOMISOL phase 1/2 trial (NCT06819735), sponsored by its subsidiary Domain Therapeutics Australia Pty Ltd, tests it alone and with an immune checkpoint inhibitor in selected advanced solid tumours, with first patients dosed in Australia in October 2025. A separate investigator-sponsored phase 1 trial of DT-7012 in relapsed or refractory cutaneous T-cell lymphoma (NCT07213882) is led by Assistance Publique, Hopitaux de Paris. Other programmes include DT-9081, an EP4 receptor antagonist that entered a phase 1 trial in solid tumours in 2022 (NCT05582850), and DT-9046, a biased PAR2 antagonist for inflammatory disease. The parent company's first registered cancer trial, NCT05582850, was posted on ClinicalTrials.gov in October 2022; the Australian subsidiary's first, NCT06819735, was posted in February 2025.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Domain Therapeutics SA
- HQ: Strasbourg
- Type: biotech
- Website: https://www.domaintherapeutics.com/

## Notes

- Founding year not stated on the pages read on 29 October 2026; the company refers to 'over the last 20 years'.
- Headquarters is taken as Strasbourg from the dateline order of the October 2025 release; the company also lists Montreal and Boston.
- No financing round is recorded because no release with an amount was read.
- The bucket is approximate: the trial sponsor is a subsidiary first seen in the registry in 2025, but the parent sponsored a cancer trial in 2022.

## Sources

- Official website: https://www.domaintherapeutics.com/
- First patients dosed in DOMISOL, October 2025: https://www.domaintherapeutics.com/phase-i-ii-trial-dt-7012-targeting-ccr8-solid-tumors/
- ClinicalTrials.gov: DT-9081 phase 1 trial (NCT05582850): https://clinicaltrials.gov/study/NCT05582850
- ClinicalTrials.gov: DT-7012 in cutaneous T-cell lymphoma (NCT07213882): https://clinicaltrials.gov/study/NCT07213882

## Connected records

- cancers: [Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)](https://onco.cc/cancers/cutaneous-t-cell-lymphoma/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- trials: [Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct06819735/)

---
JSON: https://onco.cc/api/v1/entities/domain-therapeutics.json